This article is more than 5 years old. Information may no longer be current.

Genentech reports 34% increase in third-quarter sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOUTH SAN FRANCISCO, Calif. — Genentech Inc. reported total product sales of $1.941 billion for the third quarter of 2006, a 34% increase over the same quarter of 2005.

Operating revenues increased 36% to $2.384 billion from $1.752 billion in the third quarter of 2005. For the full year 2006, Genentech expects roughly 65% to 70% growth in non-GAAP earnings per share relative to 2005, according to a press release from the company.

Domestic sales increased for many products, including a 40% increase for Herceptin (trastuzumab), a treatment for metastatic breast cancer, and a 34% increase for Avastin (bevacizumab), a colorectal cancer drug that has been used off-label to treat age-related macular degeneration.

Sales of Lucentis (ranibizumab), the company's drug indicated for AMD treatment, which was launched on June 30, increased to $153 million from second quarter sales of $10 million, according to the release.